Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand’s (a Talem Affiliate) LENSai® Integrated Intelligence Technology®, Built Upon the Proprietary HYFT Index®. VICTORIA, British Columbia — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology [……
Read More
About The Author
